US and EU pharmacovigilance compared: contemporary approach for spontaneous consumer report
This article was originally published in RAJ Devices
Executive Summary
Traditionally, reports on marketed product experiences are referred to as spontaneous reports, also commonly called voluntary, unsolicited or anecdotal reports. They are different from reports arising from clinical trials with regard to expedited and periodic reporting procedures. There are several influences complicating the classification and handling. For example, it is believed that the regulatory authorities of only two countries, the US and Canada, require the collection and reporting of direct reports from consumers. Conversely, there is a significant debate internationally about the role of such cases in pharmacovigilance. Some argue that the valid reports require “medical confirmation” while others regard patient-direct reports as potentially valuable.1 Nevertheless, the current system of pharmacovigilance in other regions, such as Europe, encourages reporting of adverse drug reactions (ADRs), mainly from healthcare professionals. Underreporting is a major problem, more so in the developing world than in the developed world. Less than 3% of reports added to the WHO database in the year 2000 originated from the developing countries, although around 80% of the global population lives in the developing world. 2
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.